Fidelity SPDR Advertisement
Home > Boards > US Listed > Biotechs >

Titan Pharmaceuticals (TTNP)

TTNP RSS Feed
Add TTNP Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator Rentier, TRUTH
Search This Board:
Last Post: 11/20/2014 6:18:56 PM - Followers: 153 - Board type: Free - Posts Today: 0


 






Products


Probuphine®-This study is enrolling participants by invitation only.

Click For Link To ClinicalTrials.gov


*November 20, 2014 -  the study is 100% enrolled.
                                                                    * DrKate Glassman-Beebe- Executive Vice President and Chief Development Officer-Titan Pharmaceuticals

Click For cnn.com Link 


Sponsor:

Braeburn Pharmaceuticals


ClinicalTrials.gov Identifier:
Information provided by (Responsible Party):
NCT02180659
First received: July 1, 2014
Last updated: July 8, 2014
Last verified: July 2014
Braeburn Pharmaceuticals









Probuphine Graphic

 

 

 

Continuous Drug Delivery Technology

 

The continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (“EVA”) and a drug substance. The resulting product is a solid matrix that is placed subcutaneously, normally in the inner part of the upper arm in a simple office procedure, and is removed in a similar manner at the end of the treatment period. The drug substance is released slowly, at continuous levels, through the process of dissolution. This results in a stable blood level similar to intravenous administration. Such long-term, linear release characteristics are generally desirable as this avoids peak and trough level dosing that poses problems for many Central Nervous System (“CNS”) and other disease settings.

This continuous drug delivery technology was developed to address the need for a simple, practical method to potentially provide continuous drug administration on an outpatient basis over extended periods of up to 6-12 months. In addition to Probuphine, which is the first product to complete clinical testing that has utilized this proprietary continuous drug delivery technology, Titan has conducted initial non-clinical studies with long-term delivery of dopamine agonists demonstrating the potential of this product in the treatment of Parkinson’s disease in non-clinical models of the disease.

 



Fanapt® (iloperidone)

 

Fanapt (iloperidone) is an atypical antipsychotic approved by the FDA for the treatment of schizophrenia currently being marketed by Novartis Pharma AG (“Novartis”) in the U.S. Titan is entitled to a royalty of 8-10% of net sales of Fanapt under a sublicense agreement with Novartis that is based on a U.S. patent which expires in October 2016 (does not include a possible six-month pediatric extension).

Titan has entered into several agreements with Deerfield Management LP (“Deerfield”), which entitle Deerfield to most of the future royalty revenues related to Fanapt in exchange for cash and debt considerations, the proceeds of which have been used to advance the development of Probuphine and for general corporate purposes. Titan has retained a portion of the royalty revenue from net sales of Fanapt in excess of specified annual threshold levels; however, based on sales levels to date, it is unlikely that Titan will retain any revenue from Fanapt in the next several years, if ever. Titan does not incur any ongoing expenses associated with this product.




Company Overview



Titan Pharmaceuticals, Inc is a biopharmaceutical company focused in the development of products for the treatment of central nervous system (CNS) diseases. Titan's first out licensed product, Fanapt® (iloperidone) is an atypical antipsychotic approved in the U.S. in May 2009 for the treatment of schizophrenia in adult patients. It is currently marketed in the U.S. by Novartis Pharma, AG, and Titan is entitled to receive 8-10% of global annual sales as royalty revenue for the term of the licensed patents.

 

Titan's second product, Probuphine, is nearing completion of the Phase 3 clinical development program in the treatment of opioid addiction. Probuphine is a novel, subcutaneous implant formulation of buprenorphine designed to deliver six months of medication following single treatment. This product has already demonstrated strong positive results in the first controlled Phase 3 study for the treatment of opioid addiction. The confirmatory Phase 3 study is currently being conducted at 20 sites in the U.S., and the results of this study are expected in Q2, 2011. Additional information on the Probuphine program is available in the PRODUCTS section of this website.


 

The Company's common stock is traded on the OTC Bulletin Board Markets ([TTNP.OB] www.otcbb.com) quotations system. For further information please contact info@titanpharm.com

 

Management Team

President
Sunil Bhonsle, M.B.A.

Executive Vice President and Chief Development Officer

Katherine L. Beebe, Ph.D.

Executive Chairman

Marc Rubin, M.D.

 



Board of Directors

 
 
  






 

Strategic Alliances


In December 2012, Titan entered into a license agreement with Braeburn Pharmaceuticals Sprl (“Braeburn”) that grants Braeburn exclusive commercialization rights to Probuphine® in the United States and Canada. Titan received a non-refundable up-front license fee of $15.75 million and will receive a $50 million milestone payment upon the approval of the NDA by the FDA. Additionally, Titan will be eligible to receive up to $130 million upon achievement of specified sales milestones and up to $35 million in regulatory milestones in the event of future NDA submissions and approvals for additional indications, including chronic pain. Titan will receive tiered royalties on net sales of Probuphine ranging from the mid-teens to the low twenties.

 





Product Overview

The investigational products are at various stages of development as listed below.

Titan Pharmaceuticals Products

In addition to the potential royalty revenues from iloperidone, Titan is currently focused on adding value to the company from these assets, particularly Probuphine. Additional information on Probuphine and other programs are available in the next sections. If you are interested in learning more, please contact Sunil Bhonsle, President, at     sbhonsle@titanpharm.com

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
TTNP
Current Price
Volume:
Bid Ask Day's Range
Wiki
TTNP News: Quarterly Report (10-q) 11/13/2014 04:43:30 PM
TTNP News: Statement of Changes in Beneficial Ownership (4) 10/14/2014 12:13:05 PM
TTNP News: Statement of Changes in Beneficial Ownership (4) 10/14/2014 12:08:51 PM
TTNP News: Statement of Ownership (sc 13g) 10/10/2014 10:20:57 AM
TTNP News: Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) 10/03/2014 03:20:22 PM
PostSubject
#3684  Sticky Note ****Addicts DESPERATELY Waiting For A Lifesaver**** TRUTH 09/27/14 11:41:37 AM
#3902   Got to love all this emotion based trading/posting. Rentier 11/20/14 06:18:56 PM
#3901   Matt, it's all good, they won't have it turks 11/20/14 04:38:55 PM
#3900   https://braeburnpharmaceuticals.com/camurus-and-braeburn-pharmaceuticals-sign-ex matthewverymuch 11/20/14 02:33:22 PM
#3899   Who knows about the share price? What's up matthewverymuch 11/20/14 02:29:02 PM
#3898   I don't think you have to worry it turks 11/20/14 02:14:41 PM
#3897   The way i understand it, titan will receive matthewverymuch 11/20/14 12:22:51 PM
#3896   A little too "close to home" (with respect TRUTH 11/20/14 12:16:26 PM
#3895   Isn't that great news,since the royalties would go up? Conrado4 11/20/14 12:10:12 PM
#3894   100 shares to try and drop it...I suppose Conrado4 11/20/14 11:47:53 AM
#3893   Did investors get spooked by the braeburn news TRUTH 11/20/14 10:05:45 AM
#3892   When the manipulation is over (when it is TRUTH 11/20/14 09:57:29 AM
#3891   Did investors get spooked by the braeburn news matthewverymuch 11/20/14 09:53:01 AM
#3890   Approval may actually get us to 50 cents matthewverymuch 11/20/14 09:50:33 AM
#3889   Makes one wonder if some of the "long-term" TRUTH 11/20/14 09:43:20 AM
#3888   Unfucgingbelieveable, great news, they chit all over it, turks 11/20/14 09:36:33 AM
#3887   Finally!!! something to look forward to, personally it turks 11/20/14 08:47:05 AM
#3886   how about some chronic pain? TRUTH 11/20/14 08:28:52 AM
#3885   The countdown has officially begun. 6 months and matthewverymuch 11/20/14 08:08:43 AM
#3884   Titan Pharmaceuticals Announces Completion of Enrollment in Phase TRUTH 11/20/14 07:29:03 AM
#3883   I didn't think so....I could not find anything dbg1969 11/18/14 10:06:31 PM
#3882   It isn't published on a website matthewverymuch 11/18/14 10:03:21 PM
#3881   Link??? dbg1969 11/18/14 07:56:37 PM
#3880   Sales weren't going into the bid. Don't know matthewverymuch 11/17/14 08:00:01 PM
#3879   Sorry, must have different glasses on then you do... Rentier 11/17/14 07:41:29 PM
#3878   Looking at the trades, someone is clearly unloading matthewverymuch 11/17/14 12:10:44 PM
#3877   Yes. I read it. matthewverymuch 11/17/14 09:18:35 AM
#3876   Great article by highline research, Mr Higgins this turks 11/17/14 09:07:56 AM
#3874   Or in at .79 and had stops in Rentier 11/16/14 11:53:16 AM
#3873   those who got stuck from .80 and above. AntiMarketMaker 11/15/14 09:10:55 AM
#3872   lol, they had many long term 'stuck' investors Rentier 11/14/14 09:00:29 PM
#3871   It's in the intro,when you first log on TRUTH 11/14/14 03:03:24 PM
#3870   Updated the ibox....not sure what that means.. matthewverymuch 11/14/14 02:56:50 PM
#3869   90% full... TRUTH 11/14/14 02:51:02 PM
#3868   Good choice. matthewverymuch 11/14/14 12:37:24 PM
#3867   I am back in at .459 AntiMarketMaker 11/14/14 12:31:11 PM
#3866   Oh...and many "long-term" investors now on board matthewverymuch 11/14/14 12:24:45 PM
#3865   90% full...still putzing around with learning how things matthewverymuch 11/14/14 11:46:22 AM
#3864   Time for the cc....here goes nothing. matthewverymuch 11/14/14 11:02:40 AM
#3863   That's a relief...phew..! matthewverymuch 11/13/14 03:40:15 PM
#3862   Who are these "mystery investors" who snatched up TRUTH 11/13/14 12:27:14 PM
#3861   Who are these "mystery investors" who snatched up matthewverymuch 11/13/14 12:20:20 PM
#3860   Titan Pharmaceuticals EPS And Revenue In Llne TRUTH 11/13/14 10:44:52 AM
#3859   Titan Pharmaceuticals Announces Third Quarter 2014 Financial Results TRUTH 11/13/14 09:11:09 AM
#3858   Ridiculous amount of selling today matthewverymuch 11/12/14 06:20:14 PM
#3857   suspect Brauburn was driving force in adding these two. TRUTH 11/11/14 11:40:11 AM
#3856   I find it interesting that the chairman and TRUTH 11/11/14 11:34:50 AM
#3855   Bayer is partner that dumped them after Spheramine Rentier 11/11/14 11:28:20 AM
#3854   I find it interesting that the chairman and matthewverymuch 11/11/14 11:25:20 AM
#3853   Can imply pro neura has a few TRUTH 11/11/14 11:20:37 AM
#3852   Meh....nothing. wasn't expecting anything...positive move on titan's part, matthewverymuch 11/11/14 10:17:31 AM
PostSubject